Enterprise Value

-7.235M

Cash

90.26M

Avg Qtr Burn

-12.59M

Short % of Float

7.02%

Insider Ownership

15.87%

Institutional Own.

62.45%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Soticlestat (OV935) Details
Rare genetic disease, Rare diseases, Dravet syndrome, Lennox-Gastaut syndrome

Phase 3

Update

OV888 (GV101) Details
Cerebral cavernous malformation

Phase 2

Initiation

Phase 1

Data readout

OV101 (δ-selective GABAA receptor agonist) (gaboxadol) Details
Genetic disorder, Rare genetic disease, Angelman Syndrome

Failed

Discontinued

OV101 (gaboxadol) Details
Rare genetic disease, Fragile X syndrome

Failed

Discontinued

OV935 (CH24H Inhibitor) Details
Rare diseases, Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder, Rare genetic disease

Failed

Discontinued